SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability

Atorvastatin, prescribed for the treatment of hypercholesterolemia, demonstrated overwhelming benefits in reducing cardiovascular morbidity and mortality. However, many patients discontinue therapy due to adverse reactions, especially myopathy. The Dutch Pharmacogenetics Working Group (DPWG) recomme...

Full description

Bibliographic Details
Main Authors: Pablo Zubiaur, Maria Dolores Benedicto, Gonzalo Villapalos-García, Marcos Navares-Gómez, Gina Mejía-Abril, Manuel Román, Samuel Martín-Vílchez, Dolores Ochoa, Francisco Abad-Santos
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Personalized Medicine
Subjects:
atorvastatin
pharmacogenetics
SLCO1B1
precision medicine
Online Access:https://www.mdpi.com/2075-4426/11/3/204

Internet

https://www.mdpi.com/2075-4426/11/3/204

Similar Items